Sep 2026· Frontiers in Systems Biology· Vol 6· 0 citations· 84 references
Medicine
TL;DR
This review provides a comprehensive, systems-level framework for translational discovery in cardiovascular disease, synthesizing advances in multi-omics technologies, network biology, artificial intelligence, and bioinformatics applied to conditions including thoracic aortic aneurysm, heart failure, valvular disease, and vascular remodeling.
Abstract
Cardiovascular diseases remain a leading cause of global morbidity and mortality, driven by the complex interplay of genetic, epigenetic, transcriptomic, proteomic, and metabolic networks. Traditional reductionist approaches have inadequately captured this molecular complexity, motivating the emergence of integrative multi-omics and systems biology as foundational paradigms in cardiovascular research. This review provides a comprehensive, systems-level framework for translational discovery in cardiovascular disease, synthesizing advances in multi-omics technologies, network biology, artificial intelligence, and bioinformatics applied to conditions including thoracic aortic aneurysm, heart failure, valvular disease, and vascular remodeling. We survey the landscape of publicly available omics repositories and examine how transcriptomics, epigenomics, proteomics, and metabolomics are being integrated to decipher disease mechanisms. We outline network-based analytical frameworks encompassing protein-protein interaction networks, gene co-expression networks, hub gene analysis, and multiplex network modeling, highlighting their utility in identifying causal molecular drivers and therapeutically actionable targets. The growing contribution of machine learning, deep learning, and multimodal artificial intelligence to cardiovascular genomics is critically examined alongside challenges of interpretability and clinical validation. Finally, we address the translational interface between systems-level discovery and precision cardiovascular medicine, including polygenic risk stratification, multi-omics biomarker development, and the path from computational prediction to clinical implementation.
To elucidate the molecular characteristics of synergistic interactions across the clinical stages of coronary heart disease (CHD)—specifically stable angina pectoris (SAP), unstable angina pectoris (UAP), and acute myocardial infarction (AMI)—through integrated metabolomic and proteomic analyses. Based on a cohort incl...
Xi-Lun Tan, Yuanxiaoxue Gao, Jia Wang et al.· Scientific Reports· 0 citations
The value of MODPM lies not in stacking additional data layers but in building a multiscale, continuously learnable framework to link biological heterogeneity to clinically interpretable and actionable decisions.
Recent technological advances and applications of multi-omics in kidney diseases are critically reviewed, with particular attention to biomarker discovery and clinical translation, and the challenges and future directions of multi-omics integration and its application in precision medicine are discussed.
It is reported that no biomarker derived from integrated transcriptomic-metabolomic analysis has undergone analytical validation, entered regulatory qualification, or reached clinical implementation, and that where diagnostic performance is reported it belongs to a single-platform model rather than to the integrated si...
Kashyap N. Thummar, Sneha M. Nair, Foram K. Ravat et al.· Critical reviews in analytic...· 0 citations
A novel eight-gene signature associated with ischemic stroke is identified and resveratrol effectively modulates these genes through coordinated regulation of neuroinflammation, mitochondrial function, apoptosis, and metabolic pathways, and the multi-target therapeutic profile of resveratrol positions it as a promising...
S. Nirala, Sandeep Kumar Shah· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.